(NASDAQ: VERU) Veru's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.
Veru's earnings in 2026 is -$13,608,554.On average, 4 Wall Street analysts forecast VERU's earnings for 2027 to be -$17,130,457, with the lowest VERU earnings forecast at -$18,881,524, and the highest VERU earnings forecast at -$15,038,382. On average, 4 Wall Street analysts forecast VERU's earnings for 2028 to be -$10,086,969, with the lowest VERU earnings forecast at -$11,529,426, and the highest VERU earnings forecast at -$8,414,333.
In 2029, VERU is forecast to generate -$13,217,408 in earnings, with the lowest earnings forecast at -$12,699,078 and the highest earnings forecast at -$13,606,155.